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Summary LY 121019, a new antifungal 
antibiotic agent, was tested for activity 
against 200 clinical isolates of Candab and 
other yeast-like fungi. LY 121019 had its 
greatest inhibitory effect on C. albicans, and 
C. tropicalis. C. glabrata and most other 
Canciida species were not as sensitive. Crypto- 
coccus and other yeast-like fungi, with the 
exception of a few strains, were not suscep 
tible to LY 121019. 
Zusammenfassung: LY 121019, ein neues 
Antimyzetikum, wurde auf seine Aktivitat 
gegen 200 klinische Isolate von Candab und 
anderen, hefeahnlichen P h n  untersucht. LY 
121019 hat seine groSte Hemmwirkung gegen 
C. albicans und C. tropicalis. C. glabrata und 
die meisten anderen Candida-Arten waren 
nicht so empfmdlich. Cryptococcus und ande- 
re, hefeiihnliche P h e  waren, mit Ausnahme 
weniger Stiimme, nicht fur LY 121019 emp 
findlich. 
Introduction 
LY 121019, an analog of the polypeptide 
antifungal antibiotic echinocandin B, ap- 
pears to possess antifungal activity primarily 
against Candida species (2, 3, 5, 6). Its 
antifungal action probably results from 
inhibition of the biosynthesis of P-1,3-glucan, 
causing severe damage to the cell wall of 
yeasts (2). The aim of this study was to 
investigate the inhibitory and fungicidal 
effects of LY 121019 on clinical isolates of 
Candida species as well as other yeast-like 
fungi. 
Materials and Methods 
Fungi 
Two hundred isolates of Candida and other 
yeast-like fungi maintained in our laboratory 
were examined. These organisms were from 
two sources: isolates from patients with 
fungemia, meningitis, and similar deep 
seated infections and isolates from patients 
participating in a study of fungal coloniza- 
tion. Organisms from overnight slant cultur- 
es on Sabouraud glucose agar, (Difco, Inc., 
Detroit, MI.) were suspended in 0.9% saline 
to a concentration of 2 x lo7 CFU/ml (0.55 
optical density reading at 660 nm in a 
spectrophotometer). A dilution of 1 :2000 in 
Sabouraud glucose broth, pH 5.5, (Difco, 
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Inc.), gave a final inoculum of 1 x lo4 
CFU/ml. 
Antifingal agent 
LY 121019, (Lilly Research Laboratories, 
Indianapolis, Indiana) was solubilized in 
50% ethanol at a concentration of lo00 
pg/ml. A further dilution of 1:12.5 in 
Sabouraud glucose broth gave a final con- 
centration of 80 pdml. 
Determination of minimum inhibitory 
concentration (MIC) 
Microtiter plates with 96 U bottom wells 
(Flow Laboratories, Inc., M c k n  VA), were 
used. Sabouraud's glucose broth (100 $) was 
pipetted into each well. The solution con- 
taining 80 pdml LY 121019 (100 $) was 
added to the first well of each row. Serial 
two-fold dilutions were made across the 
plate using a Costar octapette (Costar, Inc., 
Cambridge, MA). The final well received no 
drug, serving as a positive growth control. 
The concentration of drug ranged from 0.04 
pdml to 40 pdml. Each fungal isolate (100 
pl) was added to each of the 12 wells in a row 
at a concentration of 1 x lo4 CFU/ml. 
The plates were incubated at 30°C for 24 
to 48h. The MIC was determined as the 
lowest concentration showing no visible 
turbidity using a microtiter plate reader. The 
MIC,, was the concentration of drug which 
inhibited 50% of the isolates and the MIC,, 
was that concentration of drug which inhi- 
bited 90% of the isolates. 
Determination of minimum fungicidal 
Concentration (MFC) 
After reading the MIC for each organism, a 
lOpl sample was taken from those wells 
which showed no turbidity and plated on 
Sabouraud's glucose agar. After incubation 
at 30°C for 24h, the MFC was read as the 
lowest concentration of drug in which only 1 
or no hngal colonies persisted. The MFC,, 
was the concentration of drug which killed 
50% of the isolates while the MFC9, was 
that concentration of drug which killed 90% 
of the isolates. 
The MIC,, and MIC,, for 74 strains of C. 
albicans were 0.31pdml and 0.62pg/ml, 
respectively, with a range from 0.08 pdml to 
>40pdml (Table 1). Only 2 organisms had 
MIC's >0.62; both of these isolates had 
MICs of > 40 pdml. Most C. tropicalis were 
susceptible, but the MIC9, was >40pg/ml. 
As noted in Table 1, other species of Candida 
were generally less susceptible to LY 121019 
than C. albicans and C. tropicalis. 
The MFC,, and MFC,, for all strains of 
Candida were high (Table 1). LY 121019 was 
fungicidal at 2.5 pdml or less for 31% of C. 
albicans and 37% of C. tropicalis. In those 
strains of C. albicans and C. tropicalis in 
which the MFC was low (0.625 - 2.5 pdml), 
there was a paradoxical effect or Eagle 
phenomenon noted on the MFC plates. 
Although the organism was killed by fairly 
low concentrations of drug, growth occurred 
again at the highest concentrations of LY 
121019. 
The sensitivity of Cryptococcus and other 
yeast-like fungi to LY 121019 is shown in 
Table 2. Except for 2 strains with MIC's of 
Spdml, Cr. neoformans was resistant to LY 
121019. The few strains of Cr. laurentii tested 
were susceptible to LY 121019. The MIC's 
for all other yeast-like fungi were > 40 pdml. 
Discussion 
This study was carried out to evaluate the 
spectrum of activity of LY 121019 against a 
variety of clinical yeast isolates. LY 121019 
was most active against C. albicans and C. 
tropicalis, the organisms which cause most 
episodes of disseminated candidosis (4). 
Although some strains of other species were 
susceptible to LY 121019, most were resis- 
tant. These findings are similar to those 
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Table 1: Susceptibility of Candida to LY 121019 
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Table 2 Susceptibility of Cryptococcus and other Yeast-Like Fungi to LY 121019 
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noted by others (2, 3, 5, 6). Levels of 
>lOpg/ml can be achieved in vivo in 
experimental animals; if similar concentra- 
tions are achieved in humans, LY 121019 
might be clinically useful in treating infec- 
tions due to C.  albicans and C. tropicalis. 
Even though the MIC's for most C.  
albicans and C. tropicalis were low, for many 
of these strains LY 121019 was not fungici- 
dal, a finding different from that of Hobbs et 
al. (3). Additionally, those organisms which 
had MIC's and MFC's in the range of 
0.31 pg/d  to 1.25 pg/ml showed the Eagle 
effect, with recrudescent growth at high drug 
concentrations (1). This phenomenon has 
been noted before by some authors (3,6) but 
not by others (2). The relevance of the Eagle 
effect, described most often with beta-lactam 
antibiotics, to clinical treatment of infection 
is unknown. 
Yeast-like organisms other than Candida, 
with rare exceptions, were resistant to LY 
121019. Thus, it would appear that LY 
121019 may prove to be a useful drug in 
treating certain spedic types of yeast infec- 
tions, but it will not be useful for all such 
infections. 
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